Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide

被引：3

作者：

Uemura, Keiichiro ^{[1
]}

Nishihara, Kiyoaki ^{[1
]}

Hayashi, Tokumasa ^{[1
]}

Tomiyasu, Katsuro ^{[1
]}

Matsuoka, Kei ^{[1
]}

机构：

[1] Kurume Univ, Sch Med, Dept Urol, Kurume, Fukuoka 830, Japan

来源：

JOURNAL OF INFECTION AND CHEMOTHERAPY | 2012年 / 18卷 / 05期

关键词：

Hormone-refractory prostate cancer; Intra-arterial infusion chemotherapy; Urinary retention; 5-FLUOROURACIL; DOCETAXEL; CHEMOTHERAPY; MITOXANTRONE; PREDNISONE; ADRIAMYCIN; CARCINOMA; TRIAL;

D O I：

10.1007/s10156-011-0352-9

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Although many treatments have been applied to treat hormone-refractory prostate cancer (HRPC), therapeutic outcome is not altogether satisfactory. In the case of locally recurring HRPC, uncontrolled gross hematuria, dysuria, and scalding are often experienced. We report a patient who improved following intra-arterial infusion of cisplatin (CDDP) and ifosfamide (IFM) to treat urinary retention caused by locally recurring HRPC. After chemotherapy, cancer volume was remarkably reduced and symptoms improved.

引用

页码：753 / 755

页数：3

共 15 条

[1] A COMPARATIVE CLINICAL-TRIAL OF ADRIAMYCIN AND 5-FLUOROURACIL IN ADVANCED PROSTATIC-CANCER - PROGNOSTIC FACTORS AND RESPONSE [J].

DEWYS, WD ;

BEGG, CB ;

BRODOVSKY, H ;

CREECH, R ;

KHANDEKAR, J .

PROSTATE, 1983, 4 (01) :1-11

[2]

EISENBERGER MA, 1990, PROG CLIN BIOL RES, V359, P155

[3]

Kuriyama M, 1994, CANCER CHEMOTH PHARM, V35, P27

[4]

Maki Y, 1998, JPN J UROL, V89, P657

[5] HORMONE-REFRACTORY METASTATIC PROSTATIC-CANCER TREATED WITH METHOTREXATE, CYCLOPHOSPHAMIDE PLUS ADRIAMYCIN, CIS-PLATINUM PLUS 5-FLUOROURACIL PLUS CYCLOPHOSPHAMIDE - NATIONAL PROSTATIC-CANCER PROJECT RANDOMIZED TRIAL [J].

MURPHY, GP ;

PRIORE, RL ;

SCARDINO, PT .

UROLOGY, 1988, 32 (01) :33-40

[6]

Nishimura K, 2000, CANCER, V89, P2570, DOI 10.1002/1097-0142(20001215)89:12<2570::AID-CNCR9>3.0.CO

[7]

2-H

[8] RADIOTHERAPY AND CONCOMITANT INTRA-ARTERIAL DOCETAXEL COMBINED WITH SYSTEMIC 5-FLUOROURACIL AND CISPLATIN FOR OROPHARYNGEAL CANCER: A PRELIMINARY REPORT-IMPROVEMENT OF LOCOREGIONAL CONTROL OF OROPHARYNGEAL CANCER [J].

Oikawa, Hirobumi ;

Nakamura, Ryuji ;

Nakasato, Tatsuhiko ;

Nishimura, Kohji ;

Sato, Hiroaki ;

Ehara, Shigeru .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (02) :338-342

[9] Chemotherapy for the treatment of hormone-refractory prostate cancer [J].

Petrylak, DP .

EUROPEAN UROLOGY SUPPLEMENTS, 2002, 1 (02) :15-23

[10] Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [J].

Petrylak, DP ;

Tangen, CM ;

Hussain, MHA ;

Lara, PN,J ;

Jones, JA ;

Taplin, ME ;

Burch, PA ;

Berry, D ;

Moinpour, C ;

Kohli, M ;

Benson, MC ;

Small, EJ ;

Raghavan, D ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1513-1520

← 1 2 →